Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Paclitaxel 80 mg/m2|DRUG: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15|DRUG: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15|DRUG: Nab-paclitaxel 150 mg/m2 days 1 and 15
Sponsor: Fundacion Oncosur